<DOC>
	<DOCNO>NCT01755507</DOCNO>
	<brief_summary>Evaluation efficacy different dos UDCA vs. placebo treatment Primary Sclerosing Cholangitis ( PSC ) . Identification optimal dose ( ) treatment PSC .</brief_summary>
	<brief_title>Norursodeoxycholic Acid Treatment Primary Sclerosing Cholangitis</brief_title>
	<detailed_description>Double-blind , randomize , multi-center , placebo-controlled , comparative exploratory phase II-finding trial.The study conduct four treatment group form parallel-group comparison serve compare oral treatment either 500 mg/d , 1000 mg/d 1500 mg/d norursodeoxycholic acid capsule vs . Placebo capsule treatment PSC .</detailed_description>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<criteria>1 . Signed Informed Consent 2 . Verified diagnosis PSC 3 . PSC patient without IBD 4 . Women childbearing potential apply entire duration study highly effective method birth control . 1 . History presence concomitant liver diseases 2 . Treatment UDCA within 8 week prior baseline visit . 3 . Child B/C liver cirrhosis 4 . Total bilirubin &gt; 3.0 mg/dl screen baseline . 5 . Any relevant systemic disease 6 . TSH &gt; ULN screen 7. severe concomitant cardiovascular , renal , endocrine , psychiatric disorder 8 . Any active malignant disease 9 . Known intolerance/hypersensitivity study drug 10 . Existing intended pregnancy brest feed 11 . Simultaneous participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PSC</keyword>
</DOC>